Clinical trial · Observational
Multimodal AI Predicts High-risk Pathology in Lung Cancer Associated With Cystic Airspaces
Interpretable Multimodal Artificial Intelligence Predicts High-risk Pathology in Lung Cancer Associated With Cystic Airspaces
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 16, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260916-000001
Summary
Brief summary (as posted)
The goal of this observational study is to develop and validate an artificial intelligence (AI)-based multimodal radiomics model that integrates preoperative CT imaging features and clinical data to predict pathological high-risk features in patients with lung cancer associated with cystic airspaces (LCCA). The main questions it aims to answer are: Can an AI-based multimodal radiomics model accurately predict pathological high-risk features in LCCA before surgery? Does the integration of CT imaging features and clinical variables improve preoperative risk stratification compared with imaging or clinical information alone?
Conditions
Conditions (1)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Lung Cancer Associated With Cystic Airspaces | — | UNRESOLVED | — |
Interventions
Interventions (0)
Data not yet available
Design
Arms and outcomes
Arms (2)
- label
- Group 1
- description
- Low-risk pathology group
- label
- Group 2
- description
- High-risk pathology group
Primary outcomes (1)
- measure
- Predictive performance of the AI-based multimodal radiomics model for pathological high-risk features in LCCA
- timeFrame
- Within 30 days after surgery
- description
- Pathological high-risk features will be determined based on the final postoperative pathological examination. The predictive performance of the AI-based multimodal model will be quantified using the area under the receiver operating characteristic curve (AUC), sensitivity, specificity, accuracy, positive predictive value, and negative predictive value.
Secondary outcomes (1)
- measure
- Area under the receiver operating characteristic curve of the multimodal, CT imaging, and tabular models for pathological high-risk features in LCCA
Eligibility
Eligibility (as posted)
- Sex
- All
- Minimum age
- 18 Years
Show eligibility criteria text
Inclusion Criteria: * 1\. Patients with non-small cell lung cancer (NSCLC) confirmed by biopsy or postoperative pathological examination. 2\. Patients who underwent surgical resection of a pulmonary tumor, including lobectomy, segmentectomy, or wedge resection. 3\. Patients with complete preoperative chest CT imaging data. 4. Patients whose preoperative chest CT showed a well-defined air-containing cystic component within the tumor, consistent with the radiological features of lung cancer associated with cystic airspaces (LCCA). 5\. Patients with available clinical and pathological data required for analysis. Exclusion Criteria: * 1\. Patients with a history of pulmonary diseases that may cause cystic lung lesions, such as pulmonary tuberculosis, pulmonary fungal infection, lymphangioleiomyomatosis (LAM), or Birt-Hogg-Dubé (BHD) syndrome. Emphysema will not be considered an exclusion criterion; however, patients with severe emphysema will be excluded if it significantly affects the identification, boundary delineation, or imaging feature assessment of the target lesion. 2\. Patients who received systemic antitumor therapy before enrollment, including chemotherapy, radiotherapy, targeted therapy, or immunotherapy. 3\. Patients with other primary malignancies. 4. Patients with missing preoperative chest CT images or CT images of insufficient quality for analysis. 5\. Patients without a definite pathological diagnosis or with incomplete pathological results. 6\. Patients with missing clinical data.
References
Publications (0)
Data not yet available